(56) **References Cited**

OTHER PUBLICATIONS

Liquid Form Compared with an Aqueous Suspension of Progesterone," Journal of Pharmaceutical Sciences, vol. 93, No. 6, Jun. 2004, pp. 1495-1502.
Ueda et al., Topical and Transdermal Drug Products, Pharmacopeial Forum, vol. 35(3) [May-Jun. 2009], 750-754.
USP, 401 Fats and Fixed Oils, Chemical Tests, Second Suplement to USP36-NF 31, pp. 6141-6151, 2013.
USP, Certificate-Corn Oil, Lot G0L404, Jul. 2013.
USP, Lauroyl Polyoxylglycerides, Safety Data Sheet, US, 5611 Version #02, pp. 1-9, 2013.
USP, Monographs: Progesterone, USP29, www.pharmacopeia.cn/v29240/usp29nf24s0__m69870.html, search done: Feb. 25, 2014.
USP, Official Monographs, Corn Oil, NF 31, pp. 1970-1971, Dec. 2013.
USP, Official Monographs, Lauroyl Polyoxylglycerides, NF 31, pp. 2064-2066, Dec. 2013.
USP, Official Monographs, Medium Chain Triglycerides, NF 31, pp. 2271-2272, Dec. 2013.
USP, Official Monographs, Mono- and Di-glycerides, NF 31, pp. 2101, Dec. 2013.
U.S. Appl. No. 12/561,515 Jan. 29, 2013 Advisory Action.
Final Office Action dated Oct. 26, 2012 in U.S. Appl. No. 12/561,515.
Notice of Allowance dated Sep. 11, 2013 in U.S. Appl. No. 12/561,515.
Office Action dated Dec. 12, 2011 in U.S. Appl. No. 12/561,515.
U.S. Appl. No. 13/684,002 Mar. 20, 2013 Non-Final Office Action.
U.S. Appl. No. 13/684,002 Jul. 16, 2013 Final Office Action.
U.S. Appl. No. 13/684,002 Dec. 6, 2013 Notice of Allowance.
U.S. Appl. No. 13/843,362 Mar. 16, 2015 Restriction Requirement.
U.S. Appl. No. 13/843,428 Apr. 14, 2015 Restriction Requirement.
U.S. Appl. No. 14/099,545 Feb. 18, 2014 Non-Final Office Action.
U.S. Appl. No. 14/099,545 Jul. 14, 2014 Notice of Allowance.
U.S. Appl. No. 14/099,562 Feb. 20, 2014 Restriction Requirement.
U.S. Appl. No. 14/099,562 Mar. 27, 2014 Non-Final Office Action.
U.S. Appl. No. 14/099,562 Jul. 2, 2014 Final Office Action.
U.S. Appl. No. 14/099,562 Dec. 10, 2014 Notice of Allowance.
U.S. Appl. No. 14/099,571 Mar. 28, 2014 Restriction Requirement.
U.S. Appl. No. 14/099,571 Jul. 15, 2014 Notice of Allowance.
U.S. Appl. No. 14/099,582 Apr. 29, 2014 Restriction Requirement.
U.S. Appl. No. 14/099,582 Jun. 17, 2014 Non-Final Office Action.
U.S. Appl. No. 14/099,582 Nov. 7, 2014 Notice of Allowance.
U.S. Appl. No. 14/099,582 Jan. 22, 2015 Notice of Allowance.
U.S. Appl. No. 14/099,598 May 13, 2014 Restriction Requirement.
U.S. Appl. No. 14/099,598 Jul. 3, 2014 Non-Final Office Action.
U.S. Appl. No. 14/099,598 Dec. 10, 2014 Notice of Allowance.
U.S. Appl. No. 14/099,612 Mar. 20, 2014 Restriction Requirement.
U.S. Appl. No. 14/099,612 Oct. 30, 2014 Non-Final Office Action.
U.S. Appl. No. 14/099,612 Nov. 26, 2014 Notice of Allowance.
U.S. Appl. No. 14/099,623 Mar. 5, 2014 Restriction Requirement.
U.S. Appl. No. 14/099,623 Jul. 18, 2014 Non-Final Office Action.
U.S. Appl. No. 14/099,623 Dec. 15, 2014 Notice of Allowance.
U.S. Appl. No. 14/103,355 Dec. 8, 2014 Non-Final Office Action.
U.S. Appl. No. 14/106,655 Jul. 3, 2014 Restriction Requirement.
U.S. Appl. No. 14/125,554 Dec. 5, 2014 Restriction Requirement.
U.S. Appl. No. 14/125,554__Apr. 14, 2015__Non-Final__Office__Action.
U.S. Appl. No. 14/136,048__Nov. 4, 2014__Restriction__Requirement.
U.S. Appl. No. 14/136,048__Mar. 12, 2015__Non-Final__Office__Action.
U.S. Appl. No. 14/475,814__Oct. 1, 2014__Non-Final__Office__Action.
U.S. Appl. No. 14/475,814__Feb. 13, 2015__Notice__of__Allowance.
U.S. Appl. No. 14/475,864__Feb. 11, 2014__Notice__of__Allowance.
U.S. Appl. No. 14/475,864__Oct. 2, 2014__Non-Final__Office__Action.
U.S. Appl. No. 14/476,040__Mar. 26, 2014__Restriction__Requirement.
U.S. Appl. No. 14/521,230__Dec. 5, 2014__Restriction__Requirement.
U.S. Appl. No. 14/521,230__Feb. 18, 2015__Non-Final__Office__Action.
Utian, Wulf H, et al., Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens, Fertility and Sterility, vol. 75(6) pp. 1065, Jun. 2001.
Voegtline et al., Dispatches from the interface of salivary bioscience and neonatal research, Frontiers in Endocrinology, Mar. 2014, vol. 5, article 25, 8 pages.
Waddell et al., Distribution and metabolism of topically applied progesterone in a rat model, Journal of Steroid Biochemistry & Molecular Biology 80 (2002) 449-455.
Waddell et al., The Metabolic Clearance of Progesterone in the Pregnant Rat: Absence of a Physiological Role for the Lung, Biology of Reproduction 40, 1188-1193 (1989).
Walter et al., The role of progesterone in endometrial angiogenesis in pregnant and ovariectomised mice, Reproduction (2005) 129 765-777.
Weber, E.J., Corn Lipids, Cereal Chem., vol. 55(5), pp. 572-584, The American Assoc of Cereal Chem, Sep.-Oct. 1978.
Weber, M.T., et al., Cognition and mood in perimenopause: A systematic review and meta-analysis, J. Steroid Biochem. Mol. Biol. (2013), Elsevier.
Weintraub, Arlene, "Women fooled by untested hormones from compounding pharmacies," Forbes, Feb. 20, 2015; retrieved online at http://onforb.es/1LIUm1V on Feb. 23, 2015, 3 pages.
Whitehead et al., Absorption and metabolism of oral progesterone, The British Medical Journal, vol. 280, No. 6217 (Mar. 22, 1980), pp. 825-827, BMJ Publishing Group.
Wiranidchapong, Chutima, Method of preparation does not affect the miscibility between steroid hormone and polymethacrylate, Thermochimica Acta 485, Elsevier, pp. 57, 2009.
Wood et al., Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys, Breast Cancer Res Treat (2007) 101:125-134.
Wren et al., Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women, Climacteric, 2000, 3(3), pp. 155-160. http://dx.doi.org/10.1080/13697130008500109.
Wu et al., Gene Expression Profiling of the Effects of Castration and Estrogen Treatment in the Rat Uterus, Biology of Reproduction 69, 1308-1317 (2003).
Yalkowsky, Samuel H, & Valvani, Shri C, Solubility and Partitioning I: Solubility of Nonelectrolytes in Water, J. of Pharmaceutical Sciences, vol. 69(8) pp. 912-922, 1980.
Yalkowsky, Samuel H, Handbook of Acqueous Solubility Data, Solutions, pp. 1110-1111, CRC Press, Boca Raton, London, New York, Wash. D.C.
Yue, W., Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis, Journal of Steroid Biochem & Mol Biology, vol. 86 pp. 477-486, 2003.
Zava, David T. et al., Percutaneous absorption of progesterone, Maturitas 77 (2014) 91-92, Elsevier.
Zava, David T., Topical Progesterone Delivery and Levels in Serum, Saliva, Capillary Blood, and Tissues, Script, ZRT Laboratory, pp. 4-5. http://www.zrtiab.com/component/docman/cat_view/10-publications?Itemid.

* cited by examiner